Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Exclusion Criteria

• •Pregnant women or women who may wish to become pregnant during the course of the study.
• •Males and females of reproductive potential who are unwilling to use 2 forms of effective birth control throughout the duration of study treatment and for at least 6 months after the last dose of RBV. One method should include a condom with spermicide for males. Males must agree to refrain from sperm donation for at least 6 months after the last dose of RBV.
• •Evidence of infection or co-infection with a non-genotype 1 HCV strain.
• •Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
• •Lactating females